CTOs on the Move

Homology Medicines

www.homologymedicines.com

 
Homology is based on groundbreaking science that harnesses the naturally occurring process of homologous recombination. This non-nuclease-based approach offers clear advantages in its precision, efficiency and on-target in vivo editing of genetic mutations. Homology obtained an exclusive worldwide license to this technology platform, which is based on the pioneering research of Saswati Chatterjee, Ph.D., Professor of Virology at the Beckman Research Institute at the City of Hope in California, member of the Recombinant DNA Advisory Committee (RAC) to the Office of the Director, National Institutes of Health (NIH) and former charter member of the Therapeutic Approaches to Genetic Diseases Study ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Homology Medicines raised $43.5M on 05/02/2016
Homology Medicines raised $83.5M on 08/01/2017

Similar Companies

Actinium Pharmaceuticals

Actinium Pharmaceuticals is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Soley Therapeutics

Soley Therapeutics is a San Francisco-based, privately-held biotechnology company that is combining artificial intelligence with unique proprietary molecular and cellular response detection for discovering and developing new efficacious drugs, using image acquisition-based approaches. We have translated decades of research by Soley`s co-founders on cell-responses to perturbations and resulting information-flow within the cell, into quantifiable high-resolution imaging to identify and accelerate the development of novel therapeutic molecules for complex diseases.

Evelo Therapeutics

Evelo Therapeutics is the latest breakthrough microbiome company from Flagship VentureLabs, the innovation foundry of Flagship Ventures.

AIKO Biotechnology

AIKO Biotechnology is a Portland, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quentis Therapeutics

Quentis is at the forefront of the next generation of immuno-oncology companies that are translating novel biology into new therapeutic approaches to help more patients benefit from immunotherapy.